Contract Insights

Key Takeaways

• Pharma GxP ensures safety, quality, and compliance in contracts.
• Digital contract management is essential for audit-readiness.
• CobbleStone Software helps pharma teams meet GxP standards.

The April 2025 Presidential Executive Order, “Lowering Drug Prices by Once Again Putting Americans First,” brings forth a restructuring of the regulatory landscape for pharmaceutical and healthcare entities. These organizations are urgently analyzing current contracts and generating new agreements to comply with impending federal reforms aimed at reducing medication costs. In the heat of this scramble, powerful pharma contract management and healthcare agreement software solutions have gone from optional resources to essential assets for legal and procurement teams.

To that end, let's examine how integrated pharma contract management, healthcare agreement, and hospital procurement software solutions can help organizations easily navigate new drug pricing reforms.

This blog post was updated on March 3, 2021.

Pharmaceutical and life sciences organizations have a lot on their plate.  Unfortunately, many organizations lack an efficient process to handle a myriad of contracts, clinical trials, promotions, supplies/goods, regulations, and compliance standards.  Consequently, these organizations may leave themselves unprotected from potential increased risk, delays, compliance violations, wasted time, and squandered revenue.  Here’s how to improve life sciences and pharmaceutical contract management with accelerated contracting and compliance management.

In early June, CobbleStone exhibited at BIO 2019 in Philadelphia, PA.  There was an abundance of amazing keynotes, super sessions, fireside chats, receptions, and educational sessions ranging from “Biofuels & Renewable Chemicals” to “Value, Patient Access & Reimbursement.”  The sessions on “Business Development & Finance,” “Emerging Opportunities in Global Markets,” and “Intellectual Property” made it clear that biotechnology and pharmaceutical industry leaders from life sciences and academic institutions are eager to face their challenges. Their strategy will beintegrating new technologies into their processes to improve operations, go-to-market efforts, R&D, profitability, and contract performance.